TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB Share Price
Certificat
DE000SW88XZ5
| Market Closed - Deutsche Boerse AG 01:13:54 01/06/2024 am IST | ||
| 7.99 EUR | -1.84% |
|
| 1 month | +1.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 7.99 | -1.84% |
| 30/24/30 | 8.14 | -2.05% |
| 29/24/29 | 8.31 | +1.84% |
| 28/24/28 | 8.16 | +2.38% |
| 27/24/27 | 7.97 | -5.01% |
Delayed Quote Deutsche Boerse AG
Last update May 01, 2024 at 01:13 am IST
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW88XZ |
| ISIN | DE000SW88XZ5 |
| Date issued | 19/04/2024 |
| Strike | 2,532 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 7.31 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.58 € |
|---|---|
| Lowest since issue | 6.4 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,937
DKK
Average target price
2,466
DKK
Spread / Average Target
+27.30%
- Stock Market
- Certificates
- Certificat
